Drug combinations against Mucor irregularis In Vitro

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3395-3397

  Zhang, Shuzhen ^a   Li, Ruoyu ^a   Yu, Jin ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; DRUG POTENTIATION; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUCOR; MUCOR IRREGULARIS; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG COMBINATIONS; DRUG SYNERGISM; ECHINOCANDINS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MUCOR; MUCORMYCOSIS; NAPHTHALENES; TRIAZOLES;

EID: 84879022205     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02612-12     Document Type: Article

References (27)

1. Bonifaz A, Vázquez-González D, Tirado-Sánchez A, Ponce-Olivera RM. 2012. Cutaneous zygomycosis. Clin. Dermatol. 30:413-419.
2. Lu XL, Liu ZH, Shen YN, She XD, Lu GX, Zhan P, Fu MH, Zhang XL, Ge YP, Liu WD. 2009. Primary cutaneous zygomycosis caused by Rhizomucor variabilis: a new endemic zygomycosis? A case report and review of 6 cases reported from China. Clin. Infect. Dis. 49:e39-e43.
3. Li DM, Lun LD. 2012. Mucor irregularis infection and lethal midline granuloma: a case report and review of published literature. Mycopathologia 174:429-439.
4. Lu X-L, Najafzadeh MJ, Ran Y-P, Gerrits van den Ende AHG, Shen Y-N, Li C-Y, Xi L-Y, Hao F, Zhang Q-Q, Li R-Y, Hu Z-M, Lu G-X, Wang J-J, Drogari-Apiranthitou M, Klaassen C, Meis JF, Hagen F, Liu W-D, de Hoog GS. 2013. Taxonomy and epidemiology Mucor irregularis, agent of chronic cutaneous mucormycosis. Persoonia 30:48-56.
5. Zhao Y, Zhang Q, Li L, Zhu J, Kang K, Chen L. 2009. Primary cutaneous mucormycosis caused by Rhizomucor variabilis in an immunocompetent patient. Mycopathologia 168:243-247.
6. Tomita H, Muroi E, Takenaka M, Nishimoto K, Kakeya H, Ohno H, Miyazaki Y, Utani A. 2011. Rhizomucor variabilis infection in human cutaneous mucormycosis. Clin. Exp. Dermatol. 36:312-314.
7. Hemashettar BM, Patil RN, O'Donnell K, Chaturvedi V, Ren P, Padhye AA. 2011. Chronic rhinofacial mucormycosis caused by Mucor irregularis (Rhizomucor variabilis) in India. J. Clin. Microbiol. 49:2372-2375.
8. Abuali MM, Posada R, Del Toro G, Roman E, Ramani R, Chaturvedi S, Chaturvedi V, LaBombardi VJ. 2009. Rhizomucor variabilis var. regularior and Hormographiella aspergillata infections in a leukemic bone marrow transplant recipient with refractory neutropenia. J. Clin. Microbiol. 47:4176-4179.
9. Schell WA, O'Donnell K, Alspaugh JA. 2011. Heterothallic mating in Mucor irregularis and first isolate of the species outside of Asia. Med. Mycol. 49:714-723.
10. Enoch D, Aliyu S, Sule O, Lewis S, Karas J. 2011. Posaconazole for the treatment of mucormycosis. Int. J. Antimicrob. Agents 38:465-473.
11. Wang SB, Li RY, Yu J. 2011. Identification and susceptibility of Rhizomucor spp. isolated from patients with cutaneous zygomycosis in China. Med. Mycol. 49:799-805.
12. Krishnan-Natesan S. 2009. Terbinafine: a pharmacological and clinical review. Expert Opin. Pharmacother. 10:2723-2733.
13. Leyden J. 1998. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J. Am. Acad. Dermatol. 38:S42-S47. (Pubitemid 28215622)
14. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard-second edition: M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Sun Y, Liu W, Wan Z, Wang XH, Li R. 2011. Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis. Mycopathologia 171:111-117.
16. Gómez-López A, Cuenca-Estrella M, Mellado E, Rodríguez-Tudela JL. 2003. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagn. Microbiol. Infect. Dis. 45:199-202. (Pubitemid 36349660)
17. Dannaoui E, Afeltra J, Meis JF, Verweij PE, Eurofung Network. 2002. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob. Agents Chemother. 46:2708-2711. (Pubitemid 34793494)
18. Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. 2006. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob. Agents Chemother. 50:2248-2250. (Pubitemid 43807557)
19. Biancalana FS, Lyra L, Schreiber AZ. 2011. In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds. Antimicrob. Agents Chemother. 55:4485-4487.
20. Meletiadis J, Mouton JW, Meis JF, Verweij PE. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47:106-117. (Pubitemid 36070350)
21. Ryder NS, Leitner I. 2001. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med. Mycol. 39: 91-95. (Pubitemid 32192922)
22. Guembe M, Guinea J, Peláez T, Torres-Narbona M, Bouza E. 2007. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob. Agents Chemother. 51:3457-3458. (Pubitemid 350067580)
23. Drogari-Apiranthitou M, Mantopoulou FD, Skiada A, Kanioura L, Grammatikou M, Vrioni G, Mitroussia-Ziouva A, Tsakris A, Petrikkos G. 2012. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J. Antimicrob. Chemother. 67:1937-1940.
24. Spellberg B, Fu Y, Edwards JE, Jr, Ibrahim AS. 2005. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 49:830-832. (Pubitemid 40175710)
25. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Jr, Spellberg B. 2008. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob. Agents Chemother. 52:1556-1558. (Pubitemid 351522035)
26. Vazquez L, Mateos JJ, Sanz-Rodriguez C, Perez E, Caballero D, San Miguel JF. 2005. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica 90(12 Suppl):ECR39.
27. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards JE, Jr, Douglas CM. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727. (Pubitemid 40175685)